[
  {
    "ts": null,
    "headline": "Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52",
    "summary": "Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...",
    "url": "https://finnhub.io/api/news?id=ba428094ddd8aca60b2e150084318354d9b05444448943737329d3f0cc25e877",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770922591,
      "headline": "Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52",
      "id": 139073188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...",
      "url": "https://finnhub.io/api/news?id=ba428094ddd8aca60b2e150084318354d9b05444448943737329d3f0cc25e877"
    }
  },
  {
    "ts": null,
    "headline": "Upstream Bio’s stock drops 47% on verekitug Phase II asthma data",
    "summary": "Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.",
    "url": "https://finnhub.io/api/news?id=1184364a3fdfbc0a0e1c1966b46643ec4913d33c9d2f2e719687d9cbafc56e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770900905,
      "headline": "Upstream Bio’s stock drops 47% on verekitug Phase II asthma data",
      "id": 139056039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.",
      "url": "https://finnhub.io/api/news?id=1184364a3fdfbc0a0e1c1966b46643ec4913d33c9d2f2e719687d9cbafc56e4a"
    }
  }
]